Livongo said today that it launched its Applied Health Signals platform, which seeks to provide meaningful feedback to people living with chronic conditions using novel digital tools and artificial intelligence.
As part of its newly-launched platform, the company developed a voice-enabled, at-home cellular blood pressure monitoring system and said it would provide eligible members with co-pay waivers for medications, in an effort to encourage users to cultivate healthy behaviors.
“It’s exciting to introduce products that change the way people think about and experience chronic conditions. We did that in diabetes, with unlimited free strips, cellular-connected meters, insights and care accessible 24 hours a day anywhere, all of which made it easier for our members to stay healthy. Now we’re doing the same thing for hypertension,” chief product officer Amar Kendale said in prepared remarks. “By delivering blood pressure feedback in a new relevant way and by driving positive behavior change with medication incentives, we are reducing the confusion, complexity and cost of healthcare for our members. We are making healthcare less noisy and paving the way for meaningful and measurable change. That’s what Applied Health Signals is all about.”
Livongo’s next-generation cellular blood pressure monitoring system allows users to interact with Livongo during each use. The company’s Cuff to Cloud program enables people to upload blood pressure readings directly to the Livongo cloud.
Also today, Livongo reported that it inked a partnership with Medisafe to improve medication management for people with chronic conditions. Livongo plans to leverage its relationship with Medisafe to optimize the Applied Health Signals engine over time.
“I could not be more excited to be working with industry leaders and innovators like Medisafe,” Livongo CMO Dr. Jennifer Schneider said.”These partnerships will provide a wealth of new data into our Applied Health Signals engine, and will further our ability to apply actionable, personalized and timely health signals to our members. We are already achieving measurable clinical outcomes, and as more data comes into our engine, our fly wheel begins to spin faster, and we have the ability to affect more behavior change and improve clinical outcomes for more people with chronic conditions.”
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.